22nd Century Appoints Leading Plant Biotechnology Expert Dr. Michael Koganov to Board of Directors
September 17 2020 - 04:05PM
22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or
“the Company”), a leading plant-based, life science company driven
by next generation plant biotechnology, today announced the
appointment of Michael Koganov, Sc.D., Ph.D., to its Board of
Directors. Dr. Koganov will serve as Chair of the Company’s
Scientific and Technical Advisory Committee and as a member of its
Finance Committee.
“We are excited to welcome Michael to our
Board,” said 22nd Century’s Board Chair, Nora Sullivan. “As a
recognized expert in plant biotechnology and life science, Michael
will further strengthen our leadership team with his highly
relevant expertise related to the Company’s strategic, scientific
initiatives.”
“Michael has been a trusted scientific leader
and key advisor to many science-driven organizations and will make
a great addition to our team of experienced and talented Board
members,” said James A. Mish, Chief Executive Officer of 22nd
Century Group. “With a successful track record of developing
natural, plant-based technologies and solutions for pharmaceutical,
consumer packaged goods, and life science companies, he will bring
a valuable scientific perspective to our business and R&D
strategies. I am confident that Michael will make significant
contributions to 22nd Century as we further position ourselves as a
leading plant-based, life science company.”
Dr. Koganov is recognized as a leading expert in
the development of natural products using plant biotechnology and
has achieved considerable accomplishments in physico-chemistry,
biochemistry, bioelectrochemistry, and biotechnology. He is
credited with developing Electro-Membrane technology for the
comprehensive processing of plants to produce protein concentrates
and secondary metabolites. Dr. Koganov co-founded IBT LLC, which
developed the proprietary and sustainable Zeta Fraction™
technology. This technology selectively isolates efficacious
components from living plants and marine sources to produce a wide
range of biofunctional ingredients. After this award-winning
technology was acquired by AkzoNobel and then Ashland Global
Holdings Inc., Dr. Koganov directed the research, product
development, and commercialization of patented, multifunctional,
bioactive Zeta Fractions, which are used as key, signature
ingredients in numerous products of global companies in the OTC and
personal care spaces, as well as various synergistic compositions
of Zeta Fractions obtained from living plants from twelve major
plant families.
Dr. Koganov is the President and Co-Founder of
Intellebio LLC, a consulting and testing firm focused on the
development of novel technologies, advanced test methods, and
breakthrough products in the life science field. Dr. Koganov
received his Master of Science degree in Biochemistry from the
State University, Dnipropetrovsk, USSR; his Ph.D. in
Bioelectrochemistry from Institute of Chemical Technology,
Dnipropetrovsk, USSR; and Full Doctor of Sciences (Sc.D.) degree in
biotechnology from the Higher Attestation Commission of the USSR’s
Council of Ministers. He has written more than 70 publications,
secured over 100 granted patents, and is the author of two
books.
About 22nd Century Group, Inc.22nd Century
Group, Inc. (NYSE American: XXII) is a leading plant-based, life
science company that develops and provides unique, commercial
solutions to the life science, consumer products, and
pharmaceutical markets. Using plant genetic engineering and modern
plant breeding techniques to create new, proprietary plants and
intellectual property, 22nd Century seeks to enhance and broaden
the consumer experience by providing natural, plant-derived
ingredients to product formulators and manufacturers. In the
tobacco plant, 22nd Century is able to modulate the levels of
nicotine that naturally occur in the plant. With this technology,
22nd Century is poised to disrupt the global tobacco market with
its proprietary reduced nicotine content tobacco cigarettes
containing 95% less nicotine than conventional tobacco and
cigarettes. 22nd Century is applying its plant genetics expertise
to the hemp/cannabis plant as well to develop new and proprietary
varieties of hemp/cannabis with unique cannabinoid and terpene
profiles and desirable agronomic traits. 22nd Century also owns
or controls the rights to commercialize over 200 issued and
pending patents related to the tobacco and hemp/cannabis
plants.
Learn more at xxiicentury.com, on
Twitter @_xxiicentury and on LinkedIn.
Cautionary Note Regarding Forward Looking
Statements This press release contains forward-looking
statements concerning our business, operations and financial
performance and condition as well as our plans, objectives and
expectations for our business operations and financial performance
and condition that are subject to risks and uncertainties. All
statements other than statements of historical fact included in
this press release are forward-looking statements. You can identify
these statements by words such as “aim,” “anticipate,” “assume,”
“believe,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “potential,” “positioned,” “predict,”
“should,” “target,” “will,” “would” and other similar expressions
that are predictions of or indicate future events and future
trends. These forward-looking statements are based on current
expectations, estimates, forecasts and projections about our
business and the industry in which we operate and our management’s
beliefs and assumptions. These statements are not guarantees of
future performance or development and involve known and unknown
risks, uncertainties and other factors that are in some cases
beyond our control. All forward-looking statements are subject to
risks and uncertainties and others that could cause actual results
to differ materially from those contained in our forward-looking
statements. Please refer to the “Risk Factors” in our Annual Report
on Form 10-K filed on March 11, 2020 and in our subsequently filed
Quarterly Report on Form 10-Q. We undertake no obligation to
publicly update or revise any forward-looking statement as a result
of new information, future events or otherwise, except as otherwise
required by law.
Contacts:Mei Kuo22nd Century
Group(716) 300-1221mkuo@xxiicentury.com
John MillsICR(646)
277-1254john.mills@icrinc.com
Deirdre ThomsonICR(646)
277-1283deirdre.thomson@icrinc.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/213d1ff3-1511-4ba9-ad67-d2bc5c0e066d
22nd Century (AMEX:XXII)
Historical Stock Chart
From Feb 2024 to Mar 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2023 to Mar 2024